Fujifilm Holdings to Build a Massive Biopharma Plant

A subsidiary of the Japanese conglomerate Fujifilm Holdings Corp. said that by 2025 it would open a massive biopharmaceutical manufacturing plant in central North Carolina. It will ultimately create 725 new jobs. Government officials and Fujifilm Diosynth Biotechnologies announced the overall $2 billion project in Holly Springs. It will be billed as the most extensive end-to-end biopharmaceutical manufacturing facility in North America. The company manufactures drugs and vaccines for other companies.

Governor Cooper said, “Today’s decision shows once again that North Carolina is a world-class location for the most innovative biotech companies in the industry. Since Fujifilm Diosynth Biotechnologies already operates a facility in our state, they have complete confidence this new plant will succeed as well, thanks to North Carolina’s skilled workers, our commitment to workforce training, and the growing strength of our life science industrial cluster.”

Fujifilm Diosynth Biotechnologies, already has a campus in the nearby Research Triangle Park, which employs more than 600 people. According to the Commerce Department of the state, the company chose the Wake County site for building the plant in Texas. The company has already considered locations in College Station, Texas, Denmark, and United Kingdom.

The Fujifilm Holdings President, Kenji Sukeno, said in a news release that they are delighted to expand their North Carolina footprint. They are happy that they can fulfill their mission to help customers accelerate the development and supply of high-quality medicines to patients. The company has over thirty years of experience developing and manufacturing life-saving products like recombinant proteins, viral vectors, viral vaccines, monoclonal antibodies, and other large molecules and medical countermeasures.